MAP2K1 and melanoma: The FDA-approved anti-melanoma drug combination of trametinib and dabrafenib is evidenced here (Table 2) by the recognized relationship between the MAP2K1 and BRAF proteins in the MAPK signaling pathway and phosphorylation of its constituent proteins in melanoma tumors [13].